Coreline Soft is rapidly expanding its reach in medical research and clinical settings with its AI-based medical imaging solution, the AVIEW product line, as global interest in AI healthcare technology rises. As of 2024, the number of cumulative research publications utilizing AVIEW has reached 296, showing a remarkable increase compared to the previous year.
Stringent research and validation are essential for the successful adoption and application of AI-based medical solutions in clinical practice. Scholarly publications serve as critical evidence of a technology's reliability and efficiency, playing a decisive role in its adoption by medical professionals and researchers.
Coreline Soft’s AVIEW product line offers 3D CT image analysis solutions. AVIEW LCS Plus, which can simultaneously screen for the "BIG 3" in lung cancer screening (lung cancer, emphysema, and coronary artery calcification), supports large-scale data analysis and precise nodule detection. It reduces diagnostic variability among medical professionals and is currently supplied to lung cancer screening programs in South Korea, Europe, Germany, Italy, and more.
AVIEW CHEST is a combination medical device that analyzes lung and cardiovascular diseases with a single CT scan. Combining multiple devices into one, this system delivers comprehensive functionalities. Included in AVIEW CHEST are Coreline Soft's pre-approved products like AVIEW (COPD, CAC, Lung Texture), AVIEW Aortalab, and AVIEW LungCAD.
AVIEW CHEST automates CT image analysis, leveraging a deep learning-based network structure to automate segmentation, measurement, and analysis of anatomical structures and pathologies. It detects abnormalities like lung nodules and masses and includes an automatic aorta segmentation function.
Lee Jae-yeon, head of Coreline Soft's research team, stated, "Achieving 296 research publications as of December 2024 is not just a number; it demonstrates the credible and efficient position of medical AI," adding, "As a company trusted by researchers and clinicians, we will continue to strive to provide innovative solutions."
Coreline Soft is also smoothly expanding into the major medical market in the United States. In the first half of this year, it sold AVIEW LCS Plus, a simultaneous chest disease diagnostics product for early detection of lung cancer, emphysema, and coronary artery calcification, to UMass Memorial Medical Center, one of the top 5 hospitals in Massachusetts. Earlier this month, it also sold three major products to Temple University Hospital's Temple Lung Center, a leader in lung disease treatment.
The company is expanding its collaboration from radiology departments to key opinion leaders in pulmonology, showing meaningful results. The partnership with UMass Memorial Medical Center is particularly significant, as UMass uses Coreline Soft’s key product packages (AVIEW LCS, AVIEW CAC, AVIEW COPD).
James Lee, head of North American operations, commented, "UMass values the viewer functionality of AVIEW, including how easily radiologists can modify AI results when necessary and is very satisfied with the streamlined workflow environment that AVIEW provides."
Additionally, Coreline Soft is expanding its technology beyond comprehensive analyses of thoracic CT scans to include areas like brain, abdominal, and spinal CT, broadening its applications to cover conditions such as brain hemorrhage, cerebrovascular examinations, fatty liver quantification, body fat assessment, and spinal stenosis diagnostics.
